IBJNews

Lilly looks to double pipeline size again

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. pounded its chest a couple years ago after doubling the size of its drug pipeline to 60 molecules. Now, the company thinks it has developed a creative way to double it again in the next five years.

Indianapolis-based Lilly is developing what it calls “The Mirror Portfolio,” which it expects to grow to 45 to 60 drugs in five years. This month, Lilly announced it had secured venture-capital funding for the first two drugs in this alternative pipeline.

Lilly has committed to invest up to $150 million in three unnamed venture-capital funds, providing no more than 20 percent of the dollars the funds would use to invest in the development of early-stage drug molecules. That means Lilly eventually could have $750 million at its disposal to fund development of experimental drugs.

That pot of cash could give Lilly more resources to help develop molecules that its own scientists discover. But even more valuable, the money could give Lilly a peek at promising drugs being developed by academic researchers much earlier in the development process.

“We actually are seeing innovation opportunities that may not have come to us at this stage,” said Rob Armstrong, Lilly’s vice president of global research and development, and the architect of the Mirror Portfolio.

In this month’s deal, one of the venture firms acquired two molecules from the Mirror Portfolio—one of which was a Lilly-developed drug and one of which was from an academic institution, which Armstrong declined to name. The Lilly drug is being studied as a bone and cancer treatment. The academic drug is designed to treat congestive heart failure.

The venture-capital firm will oversee the drugs’ development, but it has chosen to contract with a Lilly subsidiary called Chorus to try to prove whether the drugs work as their researchers think they will. Such proof-of-concept studies typically take about three years.

Lilly will have first right-of-refusal to buy its drug back from the venture-capital firm. For the academic drug, it can either negotiate for that right or else be one bidder among many seeking to acquire the drug.

“This allows us to share some risk,” Armstrong said, adding, “What we’ve been able to do is provide a little bit of insight even for the venture fund about what  commercial potential a molecule may have.”

Lilly also has cloned its Chorus team, which has developed faster, more efficient ways to conduct proof-of-concept studies on early-stage molecules. There will now be a second Chorus team in Indianapolis called Chorus Resonance, as well as teams in the United Kingdom and India.

Investor Jason Chew, blogging about Lilly's Mirror Portfolio at Seeking Alpha.com, said he’s skeptical about Lilly’s strategy to reinvent its R&D model.

“The company boasts over 60 compounds in its pipeline, but has been beset lately by late-stage failures,” wrote Chew, who does not own any Lilly stock. “It hopes to begin gaining two approvals per year beginning in 2013 to dig itself out of its hole. This would be quite a feat, considering only 21 new drugs were approved by the FDA in all of 2010. Perhaps it’s time to turn away from 'innovating on innovation' and simply go back to conducting research. Perhaps cheap and fast drug development is but an illusion.”

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Angela IS the best RD

  2. We are a nation of speed. All of our younger lives are filled with deadlines, quotas and bottom lines. We start to ease out of the pressured rat-race when we finally see "retirement." The most enjoyable travel on the planet is passenger rail service. Indy to Chicago does not beat Megabus or Southwest Airlines in speed. Passenger rail however has the best seating, mammoth legroon, seat backs that recline to more than 45 degrees and employers that really want you to return as a customer. Indiana municipalities need to maintain subsidies to support this transportation mode. Losing it is loss for all of us.

  3. Good day! I just want to testify how i got my loan from Mr. Eric Lefkofsky after i applied several times from various loan lenders who claimed to also testify right in this forum,i thought the testimonies where real and i applied but they never gave me loan. I was in need of an urgent loan to start a business and i applied from various loan lenders who promised to help but they never gave me the loan. Until a friend of mine introduce me to this popular Mr. Eric Lefkofsky who promised to help me and indeed he did as he promised without any form of delay. I never thought there are still reliable loan lenders until i met Mr. Eric lefkofsky who indeed helped me with the loan and changed my belief. I promised to share this testimony after I got my loan. I don't know if you are in any way in need of a genuine and urgent loan,free feel to contact Mr. Eric Lefkofsky via their email{grouponfunding@hotmail.com}

  4. Its a THUG issue. Bleecker Street and NYX are thug bars. They attract thugs of all races. Places that attract thugs need to be kicked out of Broad Ripple. Ain't nobody got time for that!

  5. Hello everyone, My name is Marian Gareth, I am from the Texas, United State, am here to testify of how i got my loan from Mr Andre Frank {frankloancompany@yahoo.com} after i applied Two times from various loan lenders who claimed to be lenders right in this forum,i thought their lending where real and i applied but they never gave me loan. I was in need of an urgent loan to start a business and i applied from various loan lenders who promised to help but they never gave me the loan.Until a friend of mine introduce me to Mr Andre Frank the C.E.O of Andre Frank Loan Company who promised to help me with a loan of my desire and he really did as he promised without any form of delay, I never thought there are still reliable loan lenders until i met Mr Andre Frank, who really help me with my loan and changed my lief for better. I don't know if you are in need of an urgent loan, free feel to contact Mr Andre Frank on his email{ Frankloancompany@yahoo.com} for help

ADVERTISEMENT